Evidence map›Paper›PMID 34021252›Full record

ArticleLeukemia2021

Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design.

I Vaxman, S K Kumar, F Buadi, M Q Lacy, D Dingli, Y Hwa, A Fonder, M Hobbs, S Hayman, T Kourelis and 13 more

Erratum issuedOpen access · hybridAbstract readLetter
In one paragraph

Article in Leukemia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 3 institutions in 2 countries.

I VaxmanDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-8390-064X
S K KumarDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-5392-9284
F BuadiDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0003-3214-0203
M Q LacyDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
D DingliDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-7477-3004
Y HwaDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
A FonderDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
M HobbsDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
S HaymanDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
T KourelisDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-8573-9434
R WarsameDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
E MuchtarDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0003-2210-2174
N LeungDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-5651-1411
P KapoorDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
M GroganDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
R GoDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-8284-3495
Y LinDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
W GonsalvesDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
M SiddiquiDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-4640-7311
R A KyleDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
S V RajkumarDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
M A GertzDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-3853-5196
A DispenzieriDivision of Hematology, Mayo Clinic, Rochester, MN, USA. dispenzieri.angela@mayo.edu.ORCID http://orcid.org/0000-0001-8780-9512
Mayo Clinic in Arizona · USMayo Clinic · USTel Aviv University · IL

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Rafael Fonseca · 2015 to 2026
$25.5M
Paul Calabresi Program in Clinical/Translational Research at Mayo ClinicK12CA090628 · NCI · MAYO CLINIC ROCHESTER · PI WEROHA, SARAVUT · 2001 to 2025
$19.7M
NCI NIH HHS K12 CA090628NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA186781
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BiomarkersClinical Trials as TopicHumansImmunoglobulin Light-chain AmyloidosisNatriuretic Peptide, BrainPeptide FragmentsPrognosisRetrospective StudiesSurvival RateTroponin TBiomarkersNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)Troponin T

Identifiers

PMID34021252
PMCPMC8632659
OpenAlexW3161710450

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.